Cover Image
Market Research Report

Global Neutropenia Treatment Market 2017-2021

Published by TechNavio (Infiniti Research Ltd.) Product code 496062
Published Content info 70 Pages
Delivery time: 1-2 business days
Back to Top
Global Neutropenia Treatment Market 2017-2021
Published: April 26, 2017 Content info: 70 Pages

About Neutropenia Treatment

Neutropenia is an abnormal condition, characterized by critically low levels of circulating neutrophils, a type of WBC found in the blood. These cells make up for the majority of circulating lymphocytes and help defend the body against infections by bacteria, viruses, and other pathogenic organisms. Decrease in the neutrophil count in blood makes a patient susceptible to infections and may even prove fatal. Therefore, the condition requires immediate prophylaxis.

Technavio's analysts forecast the global neutropenia treatment market to grow at a CAGR of 4.45% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global neutropenia treatment market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of neutropenia drugs.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Neutropenia Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Amgen
  • Novartis
  • Teva Pharmaceutical

Other Prominent Vendors

  • Hospira
  • Pfizer

Market driver

  • Presence of branded therapies with extended version
  • For a full, detailed list, view our report

Market challenge

  • Reducing demand for chemotherapy
  • For a full, detailed list, view our report

Market trend

  • Paradigm shift in management of febrile neutropenia
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents
Product Code: IRTNTR11846

Table of Contents

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

  • Key market highlights

PART 05: Disease overview

  • Neutropenia

PART 06: Key clinical trials

PART 07: Market landscape

  • Market overview
  • Five forces analysis

PART 08: Market segmentation by drug class

  • G-CSF treatment market
  • Antibiotics treatment market
  • Antifungal drugs treatment market
  • Others
  • Geographical segmentation
  • Neutropenia market in Americas
  • Neutropenia market in EMEA
  • Neutropenia market in APAC

PART 09: Decision framework

PART 10: Drivers and challenges

  • Market drivers
  • Market challenges
  • Impact of drivers and challenges on key customer segments (pharmacy and hospitals)

PART 11: Market trends

  • Evolving payer's interest toward G-CSF biosimilars
  • Paradigm shift in management of febrile neutropenia
  • Advent of small molecules

PART 12: Vendor landscape

  • Competitive scenario

PART 13: Key vendor analysis

  • Amgen
  • Novartis
  • Teva Pharmaceutical
  • Other prominent vendors

PART 14: Appendix

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Classification of neutropenia
  • Exhibit 02: Causes of neutropenia
  • Exhibit 03: Pipeline landscape based on different drug-class
  • Exhibit 04: Pipeline snapshot based on vendors
  • Exhibit 05: Pipeline landscape based on mechanism of action
  • Exhibit 06: Pipeline landscape based on interventions
  • Exhibit 07: Global neutropenia treatment market snapshot
  • Exhibit 08: Global neutropenia treatment market 2016-2021 ($ millions)
  • Exhibit 09: Opportunity analysis in global neutropenia treatment market
  • Exhibit 10: Five forces analysis
  • Exhibit 11: Segmentation of global neutropenia market based on drug class 2016
  • Exhibit 12: Global neutropenia treatment market by G-CSF 2016-2021 ($ millions)
  • Exhibit 13: Global neutropenia treatment market by antibiotics 2016-2021 ($ millions)
  • Exhibit 14: Global neutropenia treatment market by antifungal drugs 2016-2021 ($ millions)
  • Exhibit 15: Segmentation of global neutropenia treatment market based on geography 2016
  • Exhibit 16: Global neutropenia market revenue by geography 2016-2021 ($ millions)
  • Exhibit 17: Global neutropenia market share by geography 2016-2021 (%)
  • Exhibit 18: Market scenario in Americas
  • Exhibit 19: Neutropenia treatment market in Americas 2016-2021 ($ millions)
  • Exhibit 20: Market scenario in EMEA
  • Exhibit 21: Neutropenia treatment market in EMEA 2016-2021 ($ millions)
  • Exhibit 22: Market scenario in APAC
  • Exhibit 23: Neutropenia treatment market in APAC 2016-2021 ($ millions)
  • Exhibit 24: Noteworthy examples of biosimilars approved by EMA and US FDA
  • Exhibit 25: Impact of drivers and challenges
  • Exhibit 26: Biologics approved for neutropenia treatment market by FDA since 1982
  • Exhibit 27: Global neutropenia treatment market: Competitive structure analysis 2016
  • Exhibit 28: Amgen: Key highlights
  • Exhibit 29: Amgen: Strength assessment
  • Exhibit 30: Amgen: Strategy assessment
  • Exhibit 31: Amgen: Opportunity assessment
  • Exhibit 32: Novartis: Key highlights
  • Exhibit 33: Novartis: Strength assessment
  • Exhibit 34: Novartis: Strategy assessment
  • Exhibit 35: Novartis: Opportunity assessment
  • Exhibit 36: Teva Pharmaceutical: Key highlights
  • Exhibit 37: Teva Pharmaceutical: Strength assessment
  • Exhibit 38: Teva Pharmaceutical: Strategy assessment
  • Exhibit 39: Teva Pharmaceutical: Opportunity assessment
Back to Top